Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DBVT NASDAQ:FENC NASDAQ:KERN NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$9.87-0.8%$9.73$2.20▼$12.78$270.44M-0.3632,815 shs18,275 shsFENCAdherex Technologies$8.76-3.0%$8.63$3.96▼$9.42$244.49M0.5854,664 shs40,100 shsKERNAkerna$5.89$0.17▼$6.40$64.92M3.02339,022 shs70,795 shsRNACCartesian Therapeutics$9.68-2.8%$11.58$8.46▼$26.50$251.68M0.3948,478 shs61,134 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies0.00%+8.46%-1.20%+3.35%+172.01%FENCAdherex Technologies0.00%-2.67%+4.78%+7.22%+60.15%KERNAkerna0.00%0.00%0.00%0.00%0.00%RNACCartesian Therapeutics0.00%-9.02%-14.56%-6.20%-42.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$9.87-0.8%$9.73$2.20▼$12.78$270.44M-0.3632,815 shs18,275 shsFENCAdherex Technologies$8.76-3.0%$8.63$3.96▼$9.42$244.49M0.5854,664 shs40,100 shsKERNAkerna$5.89$0.17▼$6.40$64.92M3.02339,022 shs70,795 shsRNACCartesian Therapeutics$9.68-2.8%$11.58$8.46▼$26.50$251.68M0.3948,478 shs61,134 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies0.00%+8.46%-1.20%+3.35%+172.01%FENCAdherex Technologies0.00%-2.67%+4.78%+7.22%+60.15%KERNAkerna0.00%0.00%0.00%0.00%0.00%RNACCartesian Therapeutics0.00%-9.02%-14.56%-6.20%-42.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies 2.80Moderate Buy$14.7549.44% UpsideFENCAdherex Technologies 3.00Buy$13.3352.21% UpsideKERNAkerna 0.00N/AN/AN/ARNACCartesian Therapeutics 2.80Moderate Buy$40.00313.22% UpsideCurrent Analyst Ratings BreakdownLatest KERN, RNAC, DBVT, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/15/2025FENCAdherex TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $14.007/9/2025RNACCartesian TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$21.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV Technologies$4.15M65.17N/AN/A$1.42 per share6.95FENCAdherex Technologies$47.54M5.14$0.03 per share271.24($0.21) per share-41.71KERNAkerna$13.65M0.00N/AN/A($1.52) per share0.00RNACCartesian Therapeutics$38.91M6.47N/AN/A($0.27) per share-35.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)FENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)KERNAkerna-$79.06M-$7.10N/AN/AN/A-339.99%N/A-113.03%N/ARNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/AN/AN/A-6.36%11/6/2025 (Estimated)Latest KERN, RNAC, DBVT, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/7/2025Q2 2025RNACCartesian Therapeutics-$0.76$0.50+$1.26$0.50$0.77 million$0.30 million7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AKERNAkernaN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A2.452.45FENCAdherex TechnologiesN/A4.854.59KERNAkernaN/A0.100.10RNACCartesian TherapeuticsN/A13.3313.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%FENCAdherex Technologies55.51%KERNAkerna21.97%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipDBVTDBV Technologies1.44%FENCAdherex Technologies10.98%KERNAkerna1.20%RNACCartesian Therapeutics60.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableFENCAdherex Technologies1027.91 million24.85 millionOptionableKERNAkerna11210.35 million10.23 millionNo DataRNACCartesian Therapeutics6426.00 million10.32 millionOptionableKERN, RNAC, DBVT, and FENC HeadlinesRecent News About These CompaniesCartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comNuveen LLC Purchases Shares of 27,869 Cartesian Therapeutics, Inc. $RNACSeptember 8, 2025 | marketbeat.com683 Capital Management LLC Increases Stock Position in Cartesian Therapeutics, Inc. $RNACSeptember 4, 2025 | marketbeat.comCartesian Therapeutics, Inc. $RNAC Shares Bought by MPM Bioimpact LLCSeptember 4, 2025 | marketbeat.comCartesian Therapeutics to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comErste Asset Management GmbH Buys 86,445 Shares of Cartesian Therapeutics, Inc. $RNACAugust 24, 2025 | marketbeat.comMizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)August 15, 2025 | theglobeandmail.comBTIG Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)August 14, 2025 | theglobeandmail.comOppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)August 14, 2025 | theglobeandmail.comCartesian (RNAC) Q2 Revenue Drops 99%August 9, 2025 | theglobeandmail.comCartesian Therapeutics Reports Positive Q2 2025 EarningsAugust 8, 2025 | tipranks.comCartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | taiwannews.com.twTCartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?July 24, 2025 | zacks.comWedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform RecommendationJuly 9, 2025 | msn.comWe're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateJune 21, 2025 | finance.yahoo.comCartesian Therapeutics holds annual stockholders meetingJune 17, 2025 | investing.comCartesian Therapeutics Announces New Employment Inducement GrantsJune 3, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 2, 2025 | theglobeandmail.comCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisMay 30, 2025 | globenewswire.comCartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 13, 2025 | manilatimes.netMAnalysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)May 11, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKERN, RNAC, DBVT, and FENC Company DescriptionsDBV Technologies NASDAQ:DBVT$9.65 -0.30 (-2.96%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Adherex Technologies NASDAQ:FENC$8.76 -0.27 (-2.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.79 +0.03 (+0.34%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Akerna NASDAQ:KERNAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.Cartesian Therapeutics NASDAQ:RNAC$9.68 -0.28 (-2.81%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$9.98 +0.31 (+3.15%) As of 09/12/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
